Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
8 May 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
8 May 24
8-K
Departure of Directors or Certain Officers
10 Apr 24
EFFECT
Notice of effectiveness
10 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
S-3
Shelf registration
21 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
19 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
13 Nov 23
8-K
Departure of Directors or Certain Officers
5 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
14 Aug 23
424B3
Prospectus supplement
10 Jul 23
EFFECT
Notice of effectiveness
10 Jul 23
CORRESP
Correspondence with SEC
5 Jul 23
UPLOAD
Letter from SEC
5 Jul 23
S-3
Shelf registration
30 Jun 23
D
$37.54 mm in equity, sold $37.54 mm, 34 investors
27 Jun 23
8-K
DiaMedica Therapeutics Announces $37.5 Million Private Placement
21 Jun 23
8-K
Regulation FD Disclosure
21 Jun 23
8-K
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
21 Jun 23
8-K
DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors
30 May 23
8-K
Regulation FD Disclosure
22 May 23
8-K
Amendments to Articles of Incorporation or Bylaws
18 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results
15 May 23
D
$750.00 k in equity, sold $750.00 k, 1 investor
18 Apr 23
ARS
2022 FY
Annual report to shareholders
4 Apr 23
DEFA14A
Additional proxy soliciting materials
4 Apr 23
DEF 14A
Definitive proxy
4 Apr 23
10-K
2022 FY
Annual report
28 Mar 23
8-K
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results
28 Mar 23
PRE 14A
Preliminary proxy
17 Mar 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K/A
Departure of Directors or Certain Officers
10 Mar 23
8-K
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
6 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
Latest ownership filings
4
Masuoka K. Lorianne
23 Jan 24
3
Masuoka K. Lorianne
23 Jan 24
4
Charles Pauling Semba
2 Jan 24
4
Richard Kuntz
2 Jan 24
4
Richard D. Pilnik
2 Jan 24
4
James T. Parsons
2 Jan 24
4
Randall Michael Giuffre
2 Jan 24
4
David J. Wambeke
16 Nov 23
SC 13G/A
TomEnterprise AB
27 Jun 23
SC 13G/A
TRILL AB
27 Jun 23
4
AB TomEnterprise
27 Jun 23
3
AB TRILL
27 Jun 23
4
Randall Michael Giuffre
26 Jun 23
4
Dietrich John Pauls
26 Jun 23
4
Charles Pauling Semba
26 Jun 23
4
Scott Kellen
26 Jun 23
4
David J. Wambeke
26 Jun 23
4
Richard D. Pilnik
26 Jun 23
SC 13G/A
JACINTO RICHARD II
23 Jun 23
3
RICHARD JACINTO II
23 Jun 23
4
Julie VanOrsdel Daves
2 Jun 23
4
Dominic R Cundari
2 Jun 23
4
Kirsten L Gruis
2 Jun 23
4
Scott Kellen
2 Jun 23
4
Dietrich John Pauls
2 Jun 23
4
Charles Pauling Semba
2 Jun 23
4
Richard D. Pilnik
2 Jun 23
4
James T. Parsons
2 Jun 23
4
Tanya Lewis
2 Jun 23
4
Randall Michael Giuffre
2 Jun 23
4
Richard Kuntz
30 May 23
3
Richard Kuntz
30 May 23
4
David J. Wambeke
11 Apr 23
3
David J. Wambeke
11 Apr 23
4
Tanya Lewis
6 Mar 23
3
Tanya Lewis
6 Mar 23
SC 13G/A
LYNCH TIMOTHY P
13 Feb 23
SC 13G/A
JACINTO RICHARD II
13 Jan 23
4
Randall Michael Giuffre
3 Jan 23
4
Amy L. Burroughs
3 Jan 23